Diamante Closes Euro 595,000 Seed Round Led By Arieli Capital

Jan 17, 2023•almost 3 years ago

Round Type

seed

VeronaTherapeuticsBiotechnologyHealth Care

Investors

Angels4 WomenElena Paola LanatiDiamanteArieli Capital

Description

Diamante S.r.l., a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by Arieli Capital. Offering value for global markets, Diamante is creating a groundbreaking health technology with the power to improve the health of millions of people around the world.

Company Information

Company

Diamante Srl

Location

Verona, New Jersey, United States

About

DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has achieved important results in the diagnostic field for the Rheumatoid Arthritis (RA). This project allowed the company to increase the team with two more specialized people and to develop a specific technology platform for the RA diagnoses.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns